Artificial Intelligence Approach May Help Identify Melanoma Survivors Who Face A High Risk of Cancer Recurrence
The method may help clinicians determine which patients would likely benefit from aggressive treatment even at early stages of disease.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Melanoma is a disease of the skin in which cancer cells are found in the melanocytes, the cells that produce color in the skin or pigment known as melanin.
The Melanoma & Skin Cancer Surgery Program at Massachusetts General Hospital offers expert surgical care within a multidisciplinary Cancer Center team.
Leading specialists in the Department of Radiation Oncology use advanced radiation therapy techniques to treat melanoma and other malignant skin tumors.
El tratamiento del cáncer de piel en el Centro para el Melanoma, conocido internacionalmente, ofrece novedosas terapias para personas con melanoma avanzado.
Skin cancer treatment at the internationally renowned Center for Melanoma offers novel therapies for individuals with advanced melanoma.
يُقدِّم مركز علاج سرطان الجلد الميلانيني (الصباغي) (الميلانوما) ذو الشهرة العالمية، علاجات مبتكرة للمصابين بسرطان الجلد الميلانيني المتأخر.
麻省总医院国际著名的黑色素瘤中心的皮肤癌治疗项目致力为晚期黑色素瘤患者提供新型治疗方法。
The purpose of this study was to quantify and describe the amount of waste generated by an Emergency Department, identify deviations from waste policy and explore areas for waste reduction.
Our publication keeps health care professionals up to date on the latest research and clinical advances from Mass General.
News and notes from the largest hospital-based research program in the United States
A podcast devoted to uncovering the stories of Mass General's relentless pursuit to break boundaries and provide exceptional care
The Patient Gateway provides secure online access to your health information whenever you need it. Check upcoming appointments, communicate with your doctor’s office, review medications and pay medical bills—all seamlessly online 24/7.